All News

High-grade cytokine release syndrome in the WU-CART-007 1001 trial was manageable with supportive care.

The rate of disease progression among patients with low- or intermediate-risk myelofibrosis appeared to increase over time in the MOST study.

Administering CAR T-cell therapy in an outpatient setting to patients with relapsed/refractory non-Hodgkin lymphoma was deemed feasible and safe.

Patients with 1 prior line of therapy had improved outcomes on acalabrutinib compared with those who had 2 or more prior lines.

Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.

TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment.

Those with relapsed/refractory multiple myeloma and lower tumor burden are also more likely to have deeper responses to idecabtagene vicleucel.

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.

Data from a phase 1 trial may support the utility of IBI343 for patients with advanced pancreatic ductal adenocarcinoma.

Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.

Investigators of the HEPATORCH trial will present additional data on toripalimab plus bevacizumab in this population at a future academic conference.

"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."

Public health researchers highlight how they learned to overcome and adapt to disparities observed during their careers.

Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.

Psychology intervention service may improve gratitude, anxiety, and physical function when a hematopoietic stem cell transplant is conducted vs standard of care.

Johnathan Q. Trinh, MD, et al discuss a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor.

Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.

Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.

Phase 1b data on SL-172154 in acute myeloid leukemia will be presented at the 2024 European Hematology Association Congress.

Neil M. Iyengar, MD, focuses on the use of artificial intelligence in the oncology space.

Health economists discuss their interests in the outcomes observed from the Affordable Care Act and its impact on specific populations.

Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.

Data from the phase 3 ALINA trial support the approval of alectinib for patients with ALK-positive non–small cell lung cancer in the European Union.

The FDA is expected to decide on approving osimertinib for EGFR-mutated non–small cell lung cancer in the fourth quarter of 2024.

Cathy Bradley, PhD, and Lindsay M. Sabik, PhD, spoke about moving the needle forward in the public health space through research and persistence.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.